Intuitive Surgical, Inc. $ISRG Shares Acquired by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in Intuitive Surgical by 35.3% in Q1, now holding shares worth approximately $55.56 million.
• Several other hedge funds made significant adjustments to their holdings in Intuitive Surgical during the same quarter, indicating strong institutional interest in the stock.
• Analysts have mixed ratings on Intuitive Surgical, with 13 buy ratings and a consensus target price set at $595.95, reflecting ongoing confidence despite recent fluctuations.

Woodline Partners LP raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 35.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 112,172 shares of the medical equipment provider's stock after acquiring an additional 29,283 shares during the period. Woodline Partners LP's holdings in Intuitive Surgical were worth $55,555,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ISRG. Chilton Capital Management LLC raised its holdings in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares during the period. Global Financial Private Client LLC boosted its stake in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares during the period. Elite Financial Inc. acquired a new position in Intuitive Surgical during the first quarter worth $26,000. LFA Lugano Financial Advisors SA purchased a new position in Intuitive Surgical during the 1st quarter valued at about $30,000. Finally, TD Capital Management LLC increased its stake in Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Activity at Intuitive Surgical

In other news, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider owned 19,827 shares of the company's stock, valued at approximately $9,368,059.23. This trade represents a 59.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the sale, the executive vice president owned 353 shares in the company, valued at $173,845.44. The trade was a 92.73% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,224 shares of company stock valued at $21,716,492. Insiders own 0.70% of the company's stock.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $5.87 on Thursday, reaching $455.85. The company had a trading volume of 2,180,349 shares, compared to its average volume of 2,100,207. The firm has a market capitalization of $163.41 billion, a PE ratio of 63.58, a P/E/G ratio of 4.72 and a beta of 1.61. The firm has a 50-day moving average of $487.55 and a 200-day moving average of $509.57. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the prior year, the firm earned $1.78 earnings per share. The business's quarterly revenue was up 21.4% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Truist Financial upped their price target on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Piper Sandler reiterated an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Royal Bank Of Canada restated an "outperform" rating and set a $615.00 price target on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Intuitive Surgical in a report on Friday, August 22nd. Finally, Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.